SBRX18

SBRX18 is a plant-based drug candidate being developed by Stramsen Biotech for the treatment of uterine fibroids and the management of female hormone imbalance. Developed as part of the company's SBRX series, it is derived from a proprietary database of medicinal plants. The therapeutic is designed to control the proliferation of uterine fibroids and promote hormonal equilibrium in women. While Stramsen Biotech utilizes a natural plant-based approach to drug development, SBRX18 is positioned within a biopharmaceutical pipeline aimed at clinical validation, though specific molecular targets and active chemical constituents have not been publicly disclosed.